$1800 | Single User
$3000 | Global License

Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022) - By Region (N. America, Europe, APAC, RoW); By Country (US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa)
[Report Updated: 31-03-2017]

Published by Azoth Analytics: 31 Mar 2017 | 100188 | In Stock
Related Topics: FDA , Pfizer , Roche

Introduction

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antibody Drug Conjugates Market on the basis of Analysis By Drug (Adcetris, Kadcyla), Pipeline Analysis (Developer, Phase, Indication, Status, Cytotoxic Payload, Linker, Target), By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Singapore, Brazil and South Africa).

Over the recent years, the global antibody drug conjugates industry has been growing rapidly as the global sales of Adcetris and Kadcyla have been witnessing rapid growth after their approval. Globally, the growth in the antibody drug conjugates market is driven by large number of ADC drugs in pipeline, rise in global incidences of cancer and wider therapeutic window offered by ADCs.

According to Azoth Analytics research report, “Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, global market is projected to display a robust growth represented by a CAGR of 21.82% during 2017 – 2022, chiefly driven by large number of ADC drugs in pipeline, rising number of cancer patients and wider therapeutic window offered by antibody drug conjugates.

Among the drugs, Kadcyla currently dominates the antibody drug conjugates market but will be surpassed by Adcetris in forecasted period. Among the regions, North America is predicted to advance at the highest rate, mainly driven by increase in several ADC molecules expected to gain FDA approval in next few years

The report titled, “Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, has covered and analysed the potential of Global Antibody Drug Conjugates Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global food service equipment market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Antibody Drug Conjugates Market (ADC) Market

• Adcetris Market

• Kadcyla Market

• ADC Pipeline - By Developer, Phase, Indication and Status

• ADC Pipeline - By Cytotoxic Payload, Linker and Target

Regional Markets – N. America, Europe, APAC, RoW (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Antibody Drug Conjugates Market (ADC) Market

• Adcetris Market

• Kadcyla Market

• ADC Pipeline - By Developer, Phase, Indication and Status

• ADC Pipeline - By Cytotoxic Payload, Linker and Target

Country Analysis - US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Antibody Drug Conjugates Market (ADC) Market

Other Report Highlights:

• Market Dynamics – Trends, Drivers, Challenges

• Porter’s Five Forces Analysis

• SWOT Analysis

• Policy and Regulation

• Company Analysis - Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, Progenics Pharmaceuticals

Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents
for Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022) - By Region (N. America, Europe, APAC, RoW); By Country (US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa) [Report Updated: 31-03-2017]

  • Table of Contents

    1. Research Methodology

    2. Executive Summary

    3. Strategic Recommendation

    3.1 Focus on marketing ADCs at lower cost in Asia Pacific region

    3.2 Multiple Licensing and Collaboration

    3.3 Outsourcing of ADC manufacturing to CMOs

    4. Antibody Drug Conjugates Product Overview

    5. Global Antibody Drug Conjugates Market: Growth and Forecast

    5.1 By Value (2012-2016)

    5.2 By Value (2017-2022)

    6. Global Antibody Drug Conjugates Market: By Drug (Adcetris, Kadcyla)

    6.1 Global Antibody Drug Conjugates Market-By Drug: Breakdown (%)

    6.1.1 Global Antibody Drug Conjugates Market Size and Share, By Drug, 2016

    6.1.2 Global Antibody Drug Conjugates Market Size and Share, By Drug, 2022

    6.2 Global Adcetris Market Overview

    6.2.1 By Value (2012-2016)

    6.2.2 By Value (2017-2022)

    6.3 Global Kadcyla Market Overview

    6.3.1 By Value (2013-2016)

    6.3.2 By Value (2017-2022)

    7. Global Antibody Drug Conjugates Market: Pipeline Analysis

    7.1 By Developer, Phase, Indication and Status

    7.2 By Cytotoxic Payload, Linker and Target

    8. Global Antibody Drug Conjugates Market: Regional Analysis

    8.1 Global Antibody Drug Conjugates Market, By Region: Breakdown (%)

    8.1.1 Global Antibody Drug Conjugates Market Size, By Region, 2016 (%)

    8.1.2 Global Antibody Drug Conjugates Market Size, By Region, 2022 (%)

    8.2 North America Antibody Drug Conjugates Market: An Analysis

    8.2.1 By Value (2012-2016)

    8.2.2 By Value (2017-2022)

    8.3 North America Antibody Drug Conjugates Market: By Drug

    8.3.1 North America Adcetris Market Size, By Value, 2012-2016

    8.3.2 North America Adcetris Market Size, By Value, 2017E-2022F

    8.3.3 North America Kadcyla Market Size, By Value, 2013-2016

    8.3.4 North America Kadcyla Market Size, By Value, 2017E-2022F

    8.4 North America Antibody Drug Conjugates Market: Country Analysis (U.S. and Canada)

    8.4.1 U.S. Antibody Drug Conjugates Market, By Value (2012-2022)

    8.4.2 Canada Antibody Drug Conjugates Market, By Value (2012-2022)

    8.5 Europe Antibody Drug Conjugates Market: An Analysis

    8.5.1 By Value (2012-2016)

    8.5.2 By Value (2017-2022)

    8.6 Europe Antibody Drug Conjugates Market: By Drug

    8.6.1 Europe Adcetris Market Size, By Value, 2012-2016

    8.6.2 Europe Adcetris Market Size, By Value, 2017E-2022F

    8.6.3 Europe Kadcyla Market Size, By Value, 2013-2016

    8.6.4 Europe Kadcyla Market Size, By Value, 2017E-2022F

    8.7 Europe Antibody Drug Conjugates Market: Country Analysis (Germany, France, U.K., & Rest of Europe)

    8.7.1 Germany Antibody Drug Conjugates Market, By Value (2012-2022)

    8.7.2 France Antibody Drug Conjugates Market, By Value (2012-2022)

    8.7.3 U.K. Antibody Drug Conjugates Market, By Value (2012-2022)

    8.7.4 Rest of Europe Antibody Drug Conjugates Market, By Value (2012-2022)

    8.8 Asia Pacific Antibody Drug Conjugates Market: An Analysis

    8.8.1 By Value (2012-2016)

    8.8.2 By Value (2017-2022)

    8.9 APAC Antibody Drug Conjugates Market: By Drug

    8.9.1 Asia Pacific Adcetris Market Size, By Value, 2012-2016

    8.9.2 Asia Pacific Adcetris Market Size, By Value, 2017E-2022F

    8.9.3 Asia Pacific Kadcyla Market Size, By Value, 2013-2016

    8.9.4 Asia Pacific Kadcyla Market Size, By Value, 2017E-2022F

    8.10 APAC Antibody Drug Conjugates Market: Country Analysis (China, India, Japan and Rest of Asia Pacific)

    8.10.1 Japan Antibody Drug Conjugates Market, By Value (2012-2022)

    8.10.2 China Antibody Drug Conjugates Market, By Value (2015-2022)

    8.10.3 Singapore Antibody Drug Conjugates Market, By Value (2013-2022)

    8.10.4 India Antibody Drug Conjugates Market, By Value (2015-2022)

    8.10.5 Rest of Asia Pacific Antibody Drug Conjugates Market, By Value (2013-2022)

    8.11 Rest of the World Antibody Drug Conjugates Market: An Analysis

    8.11.1 By Value (2013-2016)

    8.11.2 By Value (2017-2022)

    8.12 RoW Antibody Drug Conjugates Market: By Drug

    8.12.1 Rest of World Adcetris Market Size, By Value, 2013-2016

    8.12.2 Rest of World Adcetris Market Size, By Value, 2017E-2022F

    8.12.3 Rest of World Kadcyla Market Size, By Value, 2013-2016

    8.12.4 Rest of World Kadcyla Market Size, By Value, 2017E-2022F

    8.13 RoW Antibody Drug Conjugates Market: Country Analysis (Brazil and South Africa)

    8.13.1 Brazil Antibody Drug Conjugates Market, By Value (2014-2022)

    8.13.2 South Africa Antibody Drug Conjugates Market, By Value (2015-2022)

    8.13.3 Other Antibody Drug Conjugates Market, By Value (2013-2022)

    9. Market Dynamics

    9.1 Drivers

    9.2 Challenges

    10. Market Trends

    11. Porter’s Five Forces Analysis – Antibody Drug Conjugates Market

    12. SWOT Analysis – Antibody Drug Conjugates Market

    13. Policy and Regulatory Landscape

    14. Company Profiling

    14.1 F. Hoffmann-La Roche Ltd

    14.2 Seattle Genetics

    14.3 Takeda

    14.4 ImmunoGen Inc

    14.5 Pfizer Inc.

    14.6 Sanofi

    14.7 AbbVie Inc

    14.8 Cellldex Therapeutics

    14.9 Synthon

    15.10 Progenics Pharmaceuticals

List Of Tables
in Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022) - By Region (N. America, Europe, APAC, RoW); By Country (US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa) [Report Updated: 31-03-2017]

List of Tables

Table A: On-going Clinical Trials of Adcetris

Table B: ADC Pipeline Analysis (By Drug, Developer, Phase, Indication, Status)

Table C: ADC Pipeline Analysis (By Cytotoxic Payload, Linker, Target)

List Of Figures, Charts and Diagrams
in Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022) - By Region (N. America, Europe, APAC, RoW); By Country (US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa) [Report Updated: 31-03-2017]

List of Figures


Figure 1: Global Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 2: Global Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 3: Estimated Incidences of Global Cancer Cases, By percent, 2012

Figure 4: Estimated Incidences of Global Cancer Cases, By Percent, By Region, 2012

Figure 5: Global Antibody Drug Conjugates Market Size and Share, By Drug, 2016

Figure 6: Key Drivers

Figure 7: Global Antibody Drug Conjugates Market Size and Share, By Drug, 2022

Figure 8: Key Drivers

Figure 9: Global Adcetris Market Size, By Value, 2012-2016 (USD Million)

Figure 10: Global Adcetris Market Size, By Value, 2017E-2022F (USD Million)

Figure 11: Global Kadcyla Market Size, By Value, 2013-2016 (USD Million)

Figure 12: Global Kadcyla Market Size, By Value, 2017E-2022F (USD Million)

Figure 13: Global Antibody Drug Conjugates Market Size and Share, By Region, 2016

Figure 14: Key Drivers

Figure 15: Global Antibody Drug Conjugates Market Size and Share, By Segments, 2022

Figure 16: Key Drivers

Figure 17: North America Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 18: North America Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 19: Population aged 65 & above, 2011-2015 (% of total)

Figure 20: North America Adcetris Market Size, By Value, 2012-2016 (USD Million)

Figure 21: North America Adcetris Market Size, By Value, 2017E-2022F (USD Million)

Figure 22: North America Kadcyla Market Size, By Value, 2013-2016 (USD Million)

Figure 23: North America Kadcyla Market Size, By Value, 2017E-2022F (USD Million)

Figure 24: U.S. Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 25: U.S. Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 26: Top Cancer in US per 100,000 population, 2013

Figure 27: Canada Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 28: Canada Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 29: Percent Distribution of New Cancer Cases in Males, in Canada, 2016

Figure 30: Percent Distribution of New Cancer Cases in Females, in Canada, 2016

Figure 31: Europe Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 32: Europe Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 33: European Country Population Aged 65 and Above, 2011-2015 (% of Total)

Figure 34: Cancer Frequency in Europe, By Country, Per 100000 Population, 2012

Figure 35: Europe Adcetris Market Size, By Value, 2012-2016 (USD Million)

Figure 36: Europe Adcetris Market Size, By Value, 2017E-2022F (USD Million)

Figure 37: Europe Kadcyla Market Size, By Value, 2013-2016 (USD Million)

Figure 38: Europe Kadcyla Market Size, By Value, 2017E-2022F (USD Million)

Figure 39: Germany Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 40: Germany Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 41: Estimated Incidences of Cancer in Germany, 2012

Figure 42: Estimated Mortality of Cancer in Germany, 2012

Figure 43: France Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 44: France Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 45: Estimated Incidences of Cancer in France, 2012

Figure 46: Estimated Mortality of Cancer in France, 2012

Figure 47: U.K. Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 48: U.K. Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 49: Estimated Incidences of Cancer in U.K., 2012

Figure 50: Estimated Mortality of Cancer in U.K., 2012

Figure 51: Rest of Europe Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 52: Rest of Europe Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 53: Asia Pacific Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 54: Asia Pacific Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 55: Estimated Cases of Cancer in Asia Pacific, By Country, 2012

Figure 56: Asia Pacific Adcetris Market Size, By Value, 2012-2016 (USD Million)

Figure 57: Asia Pacific Adcetris Market Size, By Value, 2017E-2022F (USD Million)

Figure 58: Asia Pacific Kadcyla Market Size, By Value, 2013-2016 (USD Million)

Figure 59: Asia Pacific Kadcyla Market Size, By Value, 2017E-2022F (USD Million)

Figure 60: Japan Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)

Figure 61: Japan Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 62: Japan Population Aged 65 and Above, 2011-2015 (% of Total)

Figure 63: China Antibody Drug Conjugates Market Size, By Value, 2015-2016 (USD Million)

Figure 64: China Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 65: China Population Aged 65 and Above, 2011-2015 (% of Total)

Figure 66: Singapore Antibody Drug Conjugates Market Size, By Value, 2013-2016 (USD Million)

Figure 67: Singapore Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 68: India Antibody Drug Conjugates Market Size, By Value, 2015-2016 (USD Million)

Figure 69: India Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 70: Rest of Asia Pacific Antibody Drug Conjugates Market Size, By Value, 2013-2016 (USD Million)

Figure 71: Rest of Asia Pacific Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 72: Rest of World Antibody Drug Conjugates Market Size, By Value, 2013-2016 (USD Million)

Figure 73: Rest of World Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 74: Population Aged 65 and Above, By Country 2011-2015 (% of Total)

Figure 75: Rest of World Adcetris Market Size, By Value, 2013-2016 (USD Million)

Figure 76: Rest of World Adcetris Market Size, By Value, 2017E-2022F (USD Million)

Figure 77: Rest of World Kadcyla Market Size, By Value, 2013-2016 (USD Million)

Figure 78: Rest of World Kadcyla Market Size, By Value, 2017E-2022F (USD Million)

Figure 79: Brazil Antibody Drug Conjugates Market Size, By Value, 2014-2016 (USD Million)

Figure 80: Brazil Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 81: South Africa Antibody Drug Conjugates Market Size, By Value, 2015-2016 (USD Million)

Figure 82: South Africa Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 83: Others Antibody Drug Conjugates Market Size, By Value, 2013-2016 (USD Million)

Figure 84: Others Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)

Figure 85: F. Hoffmann-La Roche Ltd Segmental Break Up

Figure 86: F. Hoffmann-La Roche Ltd Geographical Break Up

Figure 87: Takeda Segmental Break Up

Figure 88: Takeda Geographical Break Up

Figure 89: Pfizer Segmental Break Up

Figure 90: Pfizer Geographical Break Up

Figure 91: Sanofi Segmental Break Up

Figure 92: Sanofi Geographical Break Up

Figure 93: AbbVie Segmental Break Up

Figure 94: AbbVie Geographical Break Up

Additional Details

Publisher

Azoth Analytics

Publisher Information

Our business research and market analysis helps organizations across different industry verticals solve their business problems. We are always scrupulous about our work and provide customized market research reports revealing the hidden truths on different verticals like pharmaceutical, oil and gas, telecommunications, real estate, logistics, energy, healthcare, technology, FMCG, food & beverages and media sectors.

Reference

100188 |

Number of Pages

154

Report Format

PDF

Azoth Analytics Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials
The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive under...
01 Nov 2016 by Current Partnering USD $2,995 More Info
Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates
Anti-CD22 Immunotherapeutics in:October 2016 R&D and Business Tracker for Antibody-Drug Conjuga...
01 Nov 2016 by La Merie USD $225 More Info
Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates
Anti-Her2 Antibody-Drug Conjugates in:September 2016 R&D and Business Tracker for Antibody-Drug ...
01 Oct 2016 by La Merie USD $225 More Info
R&D and Business Tracker for Antibody-Drug Conjugates
R&D and Business Tracker for Antibody-Drug Conjugates - a monthly update service This informa...
01 Sep 2016 by La Merie USD $1,350 More Info
4-Antibody AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary4-Antibody AG (4-Antibody), a subsidiary of Agenus, Inc. is a biopharmaceutical company that ...
29 Jul 2016 by Global Data USD $250 More Info
4-Antibody AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary4-Antibody AG (4-Antibody), a subsidiary of Agenus, Inc. is a biopharmaceutical company that ...
05 May 2016 by Global Data USD $250 More Info
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
Antibody Target, Technology & Pipeline Database: 1-Year SubscriptionTherapeutic monoclonal anti...
01 Apr 2016 by La Merie USD $1,600 More Info
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
Antibody Target, Technology & Pipeline Database: 1-Year SubscriptionTherapeutic monoclonal anti...
01 Apr 2016 by La Merie USD $1,600 More Info
4-Antibody AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary4-Antibody AG (4-Antibody), a subsidiary of Agenus, Inc. is a biopharmaceutical company that ...
08 Mar 2016 by Global Data USD $250 More Info
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeho...
30 Nov 2015 by La Merie USD $500 More Info

This report is published by Azoth Analytics

Our business research and market analysis helps organizations across different industry verticals solve their business problems. We are always scrupulous about our work and provide customized market research reports revealing the hidden truths on different verticals like pharmaceutical, oil and gas, telecommunications, real estate, logistics, energy, healthcare, technology, FMCG, food & beverages and media sectors.

Download Free Report Summary PDF

Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022) - By Region (N. America, Europe, APAC, RoW); By Country (US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa) [Report Updated: 31-03-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)